Osteoarthritis, also known as degenerative joint disease, is one the most common forms of joint disorder in the United States and affects over 20 million people. Current treatments for its management involve the use of analgesics such as acetaminophen and nonsteroidal, anti-inflammatory drugs (NSAIDs). These treatments, however, have shown…
From groundbreaking orthopedic surgery to patented oral formulas, learn how BMP-complexes like Cyplexinol® are transforming bone and joint health.
BMP-9 deficiency exacerbates joint inflammation and promotes bone loss. Researchers tested BMP-9 supplementation in mice to see if there was improvement in any of the pathophysiological features of RA. They injected BMP-9 into the knee joint at weeks 0, 2, 4, and 6 and monitored its effect via CT scan each week after injection. They also monitored BMP-9 expression in the groups that received the injection and found that expression increased significantly.
Discover how bone morphogenetic proteins (BMPs) are shifting treatment paradigms—offering regenerative solutions for bone loss and joint degeneration beyond symptom relief.
Traditional therapies slow bone loss but don’t rebuild it. This article explains how BMPs play a key role in regenerating bone and cartilage tissue through stem cell activation—transforming how we approach osteoporosis and osteoarthritis.
